Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite says Piclidenoson destroys pathological skin cells in vitro
Jan. 13, 2022 8:12 AM ETCan-Fite BioPharma Ltd. (CANF)

By: Mamta Mayani, SA News Editor

Can-Fite BioPharma (NYSE:CANF) announces that pre-clinical studies with skin cells, modeling psoriasis in humans, show that Piclidenoson destroys pathological skin cells.

The Company’s scientists reported that in a cell culture of human HaCaT cells, incubated with Piclidenoson, cell apoptosis was induced with an increase in the caspase protein, known to mediate apoptotic responses.

CANF expects to announce topline results during Q1 2022.

The study’s primary endpoint is the proportion of patients who achieve a PASI score response of ≥75% (PASI 75) vs. placebo at week 16.

Secondary endpoints include non-inferiority to Otezla in weeks 16 and 32.

Piclidenoson is a novel, A3 adenosine receptor agonist small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies.